Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$13.2 million.

  • Oncology Institute's Free Cash Flow fell 118386.57% to -$13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.7 million, marking a year-over-year increase of 2611.7%. This contributed to the annual value of -$30.3 million for FY2024, which is 2581.82% up from last year.
  • As of Q3 2025, Oncology Institute's Free Cash Flow stood at -$13.2 million, which was down 118386.57% from -$11.4 million recorded in Q2 2025.
  • Over the past 5 years, Oncology Institute's Free Cash Flow peaked at $2.2 million during Q4 2024, and registered a low of -$24.2 million during Q4 2021.
  • In the last 5 years, Oncology Institute's Free Cash Flow had a median value of -$11.4 million in 2025 and averaged -$10.7 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 1150193.55% in 2022, then surged by 14722.34% in 2024.
  • Over the past 5 years, Oncology Institute's Free Cash Flow (Quarter) stood at -$24.2 million in 2021, then surged by 33.93% to -$16.0 million in 2022, then skyrocketed by 70.27% to -$4.8 million in 2023, then surged by 147.22% to $2.2 million in 2024, then plummeted by 689.49% to -$13.2 million in 2025.
  • Its Free Cash Flow stands at -$13.2 million for Q3 2025, versus -$11.4 million for Q2 2025 and -$5.3 million for Q1 2025.